arrow_back Back to App

Limiting FDA Funds for Fiscal Year 2024

This bill proposes to cap the spending for the Food and Drug Administration (FDA) for the 2024 fiscal year. This means the FDA will have less money available for its operations, potentially affecting the speed of new drug approvals, food safety, or scientific research. Citizens might experience this through longer waits for new treatments or changes in oversight of food products.
Key points
The bill sets a maximum spending limit for the Food and Drug Administration (FDA) for 2024 at approximately $5.58 billion.
This budget limitation for the FDA could impact its ability to conduct research, inspections, and product approvals, potentially affecting drug availability and food safety.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_2295
Sponsor: Rep. Biggs, Andy [R-AZ-5]
Process start date: 2023-03-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Department of Health and Human Services, Food and Drug Administration, for fiscal year 2024.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_2295.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-29.

What are the main provisions?

Key points include:

  • The bill sets a maximum spending limit for the Food and Drug Administration (FDA) for 2024 at approximately $5.58 billion.
  • This budget limitation for the FDA could impact its ability to conduct research, inspections, and product approvals, potentially affecting drug availability and food safety.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Biggs, Andy [R-AZ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health